Skip to main content
Clinical Trials/CTRI/2021/10/037416
CTRI/2021/10/037416Not yet recruitingPhase 2

Subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after Penetrating Keratoplasty, A Prospective,Open Label,Non Comparative study

SNMedical College0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1)patients having 2 or more than 2 quadrant corneal neovascularisation
  • 2)patients who developed corneal neovascularisation during F/U ,not responding to conventional medical treatment .
  • 3)patients who gave consent to be in follow up.

Exclusion Criteria

  • 1)patients having persistent epithelial defect
  • 2)patients who were systemically not fit for subconj Bevacizumab injection;pts with H/O recent attack of M.I.,stroke and uncontrolled Hypertension.
  • 3)pregnant female

Investigators

Sponsor
SNMedical College

Similar Trials